Three selected reports address lanreotide in neuroendocrine tumors and acromegaly. The CLARINET extension follows participants from the original trial and is not an independent randomized experiment.123
Bottom line from this bounded source set
CLARINET found longer progression-free survival, without a demonstrated overall-survival or quality-of-life difference. The acromegaly study reported tumor and hormone changes but did not reject its prespecified primary null hypothesis.123
Reviewed study record
CLARINET: neuroendocrine tumors
Design
Randomized, double-blind, placebo-controlled trial over 96 weeks.1
Population
204 people with advanced nonfunctioning, somatostatin-receptor-positive grade 1 or 2 neuroendocrine tumors; most had stable disease before enrollment.1
Outcomes reported
The hazard ratio for progression or death was 0.47 (95% CI 0.30–0.73). Overall survival and quality of life did not differ significantly. Treatment-related diarrhea occurred in 26% versus 9%.1
Limitations
The selected tumor grades, receptor status and largely stable baseline disease limit generalization. Progression-free survival is distinct from longer overall survival.1
Reviewed study record
CLARINET open-label extension
Design
Eligible original-trial participants entered an extension in which everyone received lanreotide.2
The continuous-treatment group had a reported median progression-free survival of 38.5 months. Adverse-event incidence was lower during extension than during the core study.2
Limitations
Selective extension enrollment, crossover and absence of a concurrent placebo group prevent an independent randomized long-term comparison.2
Reviewed study record
PRIMARYS: acromegaly
Design
48-week open-label, single-arm study with centrally assessed tumor volume.3
Population
90 treatment-naïve people with acromegaly and growth-hormone-secreting macroadenomas entered; 64 completed.3
Outcomes reported
The primary analysis found at least 20% tumor-volume reduction in 62.9% of 89 participants, but the prespecified null hypothesis was not rejected. Hormonal and symptom measures also improved.3
Limitations
No control group, attrition and differences between primary and sensitivity analyses limit causal interpretation. No gastrointestinal-intolerance withdrawals does not mean no adverse events.3
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa1316158. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1007/s12020-020-02475-2. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1210/jc.2013-3318. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗